1. Home
  2. HAFC vs MYGN Comparison

HAFC vs MYGN Comparison

Compare HAFC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

N/A

Current Price

$25.39

Market Cap

770.0M

Sector

Finance

ML Signal

N/A

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

N/A

Current Price

$4.81

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HAFC
MYGN
Founded
1982
1991
Country
United States
United States
Employees
610
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
770.0M
481.6M
IPO Year
2000
1996

Fundamental Metrics

Financial Performance
Metric
HAFC
MYGN
Price
$25.39
$4.81
Analyst Decision
Hold
Hold
Analyst Count
3
9
Target Price
$31.33
$8.06
AVG Volume (30 Days)
213.7K
1.3M
Earning Date
04-27-2026
05-15-2026
Dividend Yield
4.35%
N/A
EPS Growth
22.44
N/A
EPS
2.51
N/A
Revenue
$270,165,000.00
$771,400,000.00
Revenue This Year
$18.65
$7.19
Revenue Next Year
$7.28
$5.64
P/E Ratio
$10.24
N/A
Revenue Growth
15.28
2.33
52 Week Low
$19.25
$3.76
52 Week High
$30.20
$11.44

Technical Indicators

Market Signals
Indicator
HAFC
MYGN
Relative Strength Index (RSI) 36.35 43.74
Support Level $24.38 $3.93
Resistance Level $25.57 $5.67
Average True Range (ATR) 0.84 0.39
MACD -0.11 0.11
Stochastic Oscillator 19.15 44.41

Price Performance

Historical Comparison
HAFC
MYGN

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: